Back to search results

Optimizing MRI for Leptomeningeal Disease Detection

This study is looking at how to improve the detection of leptomeningeal disease (LMD), a condition where cancer cells spread to the membranes surrounding the brain and spinal cord. Researchers are testing a contrast agent called VUEWAY (gadopiclenol) during MRI scans. They want to see if VUEWAY, which is given through an IV, can help find early LMD more effectively than standard MRI contrast like Gadavist. You might be able to join if you have a solid tumor with unclear LMD results from a standard brain MRI, or if you have a high risk of LMD but previous tests were negative. The main goal is to check the safety of VUEWAY and any side effects over about one year. This study aims to enroll 40 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 40 participants. The phase of the study is not specified.
What's involved
You would receive VUEWAY or Gadavist through an IV during MRI scans, which are part of your standard care.
Compensation
Not stated in the trial record.
Follow-up
Your safety and any adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07415018

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

Recruiting
NAAges 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~40 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:MRI ScanVUEWAYGadavist

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

Leptomeningeal Disease

Explore related trials

Leptomeningeal Disease

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Rami Eldaya, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Rami Eldaya, MD
[email protected]
(713) 745-2945
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target solid tumors, but if more patients are needed to meet the study power we will enroll liquid tumors.
Participants \> 18 years of age.
Participants are able to consent.

Exclusion

Participants with CSF sampling positive for LMD or MR brain/spine with definitive evidence of LMD.
Participants with implantable devices that can not be scanned with MR safe mode for participant safety.
Pregnant participants or potentially pregnant participants are at risk of contrast on the fetus

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0